Skip to Content

Antiretroviral treatment

21 February 2012
Lives in the balance: the urgent need for HIV and TB treatment in Myanmar
Lives in the balance: the urgent need for HIV and TB treatment in Myanmar
22 February 2012
An HIV patient is assessed in an MSF clinic, Myanmar.
An HIV patient is assessed in an MSF clinic, Myanmar. He is 21 years old yet weighs just 23kg.
Bangkok, Thailand – In a report released today Médecins Sans Frontières/Doctors Without Borders (MSF), the largest provider of HIV treatment in Myanmar, highlights the critical need for increased HIV and Tuberculosis (TB), including multi drug-resistant tuberculosis (MDR-TB), treatment in the country. An HIV patient is assessed in an MSF clinic, Myanmar. He is 21 years old yet weighs just 23kg. Photo: Greg Constantine   According to the report, 85,000 people in urgent need of lifesaving anti-retroviral therapy (ART) in Myanmar are today unable to access it. Of an estimated 9,300 people newly infected with MDR-TB each year, so far just over 300 have been receiving treatment...
22 February 2012
Myanmar: Kyaw Kyaw is 21 years old and weighs just 23kg.
Kyaw Kyaw is 21 years old and weighs just 23kg. His CD4 count is 168, below WHO criteria for enrollment on ART, but due to overwhelming numbers of patients even sicker than he is in its Yangon clinics, Myanmar
Maung Myint, a HIV and TB patient, tells us about his struggle to get life saving treatment in Myanmar. To help patients like Maung MSF launches a new report on the dire lack of treatment for HIV and TB in Myanmar, as donors slash future funding. Kyaw Kyaw* is 21 years old and weighs just 23kg. His CD4 count is 168, below WHO criteria for enrollment on ART, but due to overwhelming numbers of patients even sicker than he is in its Yangon clinics, MSF is not yet able to start him on the lifesaving treatment. *name has been changed. Photo: Greg Constantine Maung Myint, “I believe ART will be able to give me a normal life. I dream to be healthy again,...
14 February 2012
Norvatis: Stop the attack on generic medicines
Norvatis: Stop the attack on generic medicines
For the past 6 years drug giant Novartis has been pursuing a legal case in India that threatens access to life-saving affordable medicines for millions across the developing world. As the case now opens before the Indian Supreme Court, join MSF & tell Novartis that people matter more than profits. Join MSF & tell Novartis patients matter more than profits Not on Twitter? Send Novartis a message by email   TWITTER Option 1: Tweet one of our messages to Novartis: @Novartis People matter more than profits; stop your case against #India today bit.ly/wqj70E #STOPNovartis Leaving people w/o drugs is “like tying a rope round a person’s neck”...
01 February 2012
In 2006 the drug company Novartis took the Indian government to court over its patent law, in a move that threatened access to affordable medicines produced in India for millions of people across the developing world. The company wanted to get the law changed so that they could more easily extend the patents on their products, and stop generic companies producing the same medicines at a fraction of the price. MSF’s Drop the Case campaign, launched in response to this move, gathered nearly half a million signatures calling on the company to drop its case. But six years later, the legal battle continues. India’s Supreme Court is now due to give the final judgement on the case this year. MSF has renewed its campaign call for the...
01 February 2012
Hundreds of activists gathered in New Delhi to protest Novartis's attack on Indi
Hundreds of activists gathered in New Delhi to protest Novartis's attack on India's patent laws in 2007. MSF and others continue to oppose the legal case today.
Hundreds of activists gathered in New Delhi to protest Novartis's attack on India's patent laws in 2007. MSF and others continue to oppose the legal case today. Photo: MSF Q: Why do millions of people rely on India for affordable medicines? A: Drugs produced by companies in India are among the cheapest in the world. That is because until 2005, India did not grant patents on medicines. India is one of the few developing countries with production capacity to manufacture quality-assured generic medicines. By producing cheaper generic versions of drugs that were patented in other countries, India became a key source of affordable medicines, such as antiretroviral medicines to treat HIV/AIDS.  ...
25 November 2011
South Africa’s Budget Expenditure Monitoring Forum warns *NOTE: The Budget Expenditure Monitoring Forum [BEMF] is a group of civil society organisations concerned with HIV/AIDS funding in South Africa and the Southern African region. BEMF includes SECTION27, the Treatment Action Campaign, Médecins Sans Frontières South Africa, the Centre for Economic Governance and AIDS in Africa, the Free State AIDS Coalition and World Vision.   JOHANNESBURG –The shock announcement by the Board of the Global Fund to Fight AIDS, TB, and Malaria that financial shortfalls forced the cancellation of its Round 11 of new grants threatens to run back the clock on the gains made in the fight against HIV. The Global Fund financial...
25 January 2012
Kinshasa – Médecins Sans Frontières/Doctors Without Borders (MSF) is alarmed by the situation of HIV/AIDS patients in the Democratic Republic of Congo (DRC), the lack of priority given by the Congolese authorities and the withdrawal of donors, all occurring as the Global Fund to Fight AIDS, Malaria and Tuberculosis prepares to celebrate its tenth anniversary on 28 January. The conditions surrounding access to care for people living with HIV/AIDS in DRC are horrific. At the Centre Hospitalier de Kabinda (CHK) in Kinshasa, MSF has observed an excessively high number of patients arriving with serious complications resulting from lack of treatment. Their advanced illness creates unacceptable suffering.  "I...
30 November 2011
10 Years of antiretroviral treatment in Malawi by MSF
10 Years of antiretroviral treatment in Malawi by MSF
For people living with HIV the greatest battle is having a normal life. Up to a decade ago without readily accessible antiretroviral treatment this was unthinkable and HIV and AIDS was seen as a death sentence. Three MSF’s patients from Chiradzulu share their personal testimonies of living in good health for the last 10 years on treatment two MSF medical staff talking about preventing the transmission of HIV from mother to child, and the future challenges for HIV care in Malawi.   Read MSF’s report: 10 Years of antiretroviral treatment in Malawi by MSF 10 Years of ARVs in Malawi A brief overview of MSF's 10-year HIV treatment programme in Chiradzulu, Malawi...
30 November 2011
MSF celebrates 10 years of providing antiretroviral treatment in Malawi
MSF celebrates 10 years of providing antiretroviral treatment in Malawi
  Teaser: 1 of 8 videos - MSF celebrates 10 years of providing antiretroviral treatment in Malawi. MSF introduced ARVs in Chiradzulu (CHDZ) in 2001. Today, more than 55% of the patients who started treatment in 2001 in are still actively followed by MSF as well as alive and healthy. By September 2011, MSF is following 30,000 HIV positive patients in CHDZ, 22 000 are receiving ARVs, 12.5% of whom are children.
Syndicate content